about
Cigarette Smoke Amplifies Inflammatory Response and Atherosclerosis Progression Through Activation of the H1R-TLR2/4-COX2 AxisThe molecular targets of approved treatments for pulmonary arterial hypertensionComparison of PGH2 binding site in prostaglandin synthases.Paracrine effects of bone marrow-derived endothelial progenitor cells: cyclooxygenase-2/prostacyclin pathway in pulmonary arterial hypertension.Prostacyclin in the intensive care setting.Production of prostaglandin e(2) and i(2) is coupled with cyclooxygenase-2 in human follicular dendritic cells.PGI2 as a regulator of inflammatory diseases.The prostacyclin analog, treprostinil sodium, provides symptom relief in severe Buerger's disease--a case report and review of literature.Lung-specific RNA interference of coupling factor 6, a novel peptide, attenuates pulmonary arterial hypertension in rats.Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.Pharmacokinetic evaluation of continuous intravenous epoprostenol.Novel Targets of Drug Treatment for Pulmonary Hypertension.High altitude pulmonary edema (HAPE) in a Himalayan trekker: a case report.Selexipag for the treatment of pulmonary arterial hypertension.The prostacyclin pathway in pulmonary arterial hypertension: a clinical review.Update on pulmonary arterial hypertension pharmacotherapy.IP receptor-dependent activation of PPARgamma by stable prostacyclin analogues.Treprostinil sodium (Remodulin), a prostacyclin analog, in the treatment of critical limb ischemia: open-label study.Suppressor of cytokine signaling 1 is a positive regulator of TGF-β-induced prostaglandin production in human follicular dendritic cell-like cells.Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.Structure-function properties of the apoE-dependent COX-2 pathway in vascular smooth muscle cells.Impaired EDHF-mediated vasodilatation in adult offspring of rats exposed to a fat-rich diet in pregnancy.Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs.Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension.Iloprost, a prostacyclin (PGI2) analogue, reduces liver injury in hepatic ischemia-reperfusion in rats.The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway.Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats.
P2860
Q26776119-C271571F-9A6E-4913-94CA-36CD208BAF08Q26798308-E6333254-44F4-4C1C-898D-D98634EB5D79Q33528245-2A49CDFF-8EB9-4A4B-9D48-703CED80868FQ35048253-DE2C215D-F0E4-46F7-9B85-037F10204281Q35050464-1BF666B4-0DF3-4EE8-BB94-CA1D2B9586B9Q35745503-C21663D9-4BFD-480A-BA7E-EEB4AEB95199Q36125149-CF8BFA37-CF53-48F1-AAA0-D79ABA5A8C79Q36380897-551EF0F9-89F5-4B93-8DBB-8060444F3EBCQ37150873-16C1D695-F337-4C72-8BE3-91B6334F5BAAQ37705261-B07A2061-B6FB-4A7A-B408-B9AA43C5EF7AQ37809538-2A3F963E-61AC-4B03-81EE-9A27B1E20DBFQ38504399-4EBC9557-8018-48A4-9279-D04C2C0E3969Q38722449-CBF7342E-F6B5-4ED0-A96E-CB44D77657F4Q38836877-DF5D9FC8-5F48-4E0C-8F11-87D94B360F03Q38841958-232AF9B8-B03E-4BFE-ADD9-6F6FBC61CC90Q38846020-D99035A2-0E2E-443C-B539-2EC65824148DQ40108534-46321E20-8E9F-40B1-81C9-74B3D60C209CQ40290663-327B2F0A-BBE7-4B38-BD2D-C9EF9C9CCBF9Q41137172-35D3EB5A-DB50-4169-A697-B7A6D0DB754BQ42084867-97C6B310-4071-46A4-983D-EDC2AB4B7CB7Q42541410-91E01DDD-6D65-4C5C-9D8A-C583E74A839DQ44934638-0ED11678-4F68-4878-B0B0-2471ADFBEF4CQ45926654-FF118CAA-3C26-4544-8A40-87B12A34B077Q45960565-EBD54560-22FB-46FE-994E-9FB1E690A798Q45979153-D576A625-91EE-4E83-96F0-BD25893DAA25Q46884698-B2CF3BF0-2B4C-4874-AD20-42DA7285AD49Q50416961-838D1CC5-51C2-44C7-B2F0-9403F193EF6F
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Prostacyclin: a vascular mediator.
@ast
Prostacyclin: a vascular mediator.
@en
type
label
Prostacyclin: a vascular mediator.
@ast
Prostacyclin: a vascular mediator.
@en
prefLabel
Prostacyclin: a vascular mediator.
@ast
Prostacyclin: a vascular mediator.
@en
P1476
Prostacyclin: a vascular mediator.
@en
P304
P356
10.1016/S1078-5884(03)00385-X
P577
2003-12-01T00:00:00Z